Jason Butler
Stock Analyst at Citizens
(4.64)
# 183
Out of 5,165 analysts
141
Total ratings
50%
Success rate
46.17%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $62.13 | +54.51% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $3.25 | +146.15% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $2.79 | +581.00% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $126.62 | +3.46% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.00 | +111.11% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $65.13 | +41.26% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.11 | +191.97% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $27.73 | +0.97% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $20.90 | +77.03% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.36 | +153.91% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.54 | +69.49% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $25.07 | +298.88% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $28.60 | +32.87% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $9.90 | +81.82% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.71 | +47.60% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $706.03 | -0.71% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $2.56 | +251.56% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.46 | +194.12% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.85 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.14 | +515,870.52% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $13.27 | +774.15% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.36 | +106.42% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.01 | - | 1 | Dec 2, 2020 |
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $62.13
Upside: +54.51%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $3.25
Upside: +146.15%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $2.79
Upside: +581.00%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $126.62
Upside: +3.46%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.00
Upside: +111.11%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $65.13
Upside: +41.26%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.11
Upside: +191.97%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $27.73
Upside: +0.97%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $20.90
Upside: +77.03%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.36
Upside: +153.91%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.54
Upside: +69.49%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $25.07
Upside: +298.88%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $28.60
Upside: +32.87%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.90
Upside: +81.82%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.71
Upside: +47.60%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $706.03
Upside: -0.71%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $2.56
Upside: +251.56%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $6.46
Upside: +194.12%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $7.85
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.14
Upside: +515,870.52%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $13.27
Upside: +774.15%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.36
Upside: +106.42%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $2.01
Upside: -